NEW YORK – SpeeDx said on Monday it has agreed with Laboratory Corporation of America to codevelop diagnostic tests. The agreement focuses on assays for women's health and infectious diseases.
SpeeDx and LabCorp will work together to codevelop and introduce new molecular tests using SpeeDx's proprietary technology, the Australia-based firm said in an email. Financial terms were not disclosed.
"SpeeDx and LabCorp have a mutual goal to bring enhanced testing solutions to US patients," said Colin Denver, SpeeDx's CEO. "We are excited about the impact this collaboration can have as we support LabCorp and their ongoing commitment to bring high-quality, high-value testing services to clinicians and patients across the US," Denver added.
SpeeDx has submitted its test for molecular detection of Mycoplasma genitalium and resistance genes to the US Food and Drug Administration and anticipates approval this quarter. The firm also recently announced a collaboration with QuantuMDx and FIND to develop point-of-care testing sexually transmitted infection testing. Its M. gen test on the Cepheid FleXible cartridge system received CE mark in September and its test for gonorrhea and drug resistance is also CE marked.